BRAF and carcinoma: From a molecular point of view, poorly differentiated carcinomas defined by the Turin consensus harbor more frequently RAS mutations, while MSKCC cases are enriched with BRAF mutations [12]; 40–55% of tumors harbor TERT promoter mutations [12, 13].